The lack of efficacy was not due to impaired PARP inhibition in orthotopic tumours since olaparib treatment at doses as low as 25 mg/kg did inhibit PAR formation in tumours (Supplementary Fig. 1). The gene discussed is PARP1; the disease is neoplasm.